Metformin Aging Study to Assess Insulin Sensitivity and Mitochondrial Function
A 12-week double-blind, placebo-controlled trial will evaluate metformin's effects on insulin sensitivity and mitochondrial function in aging individuals.
Asset / Drug
Drug and asset intelligence for Metformin with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Monitor trial outcomes, particularly changes in insulin sensitivity and mitochondrial function, as well as any subsequent regulatory actions.
July 4, 2026 · N/A
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.